Value Added Technology Co., Ltd. (KOSDAQ:043150)
20,050
+180 (0.91%)
At close: Dec 5, 2025
Value Added Technology Revenue
Value Added Technology had revenue of 100.11B KRW in the quarter ending September 30, 2025, with 14.70% growth. This brings the company's revenue in the last twelve months to 413.76B, up 6.67% year-over-year. In the year 2024, Value Added Technology had annual revenue of 385.19B with 0.06% growth.
Revenue (ttm)
413.76B
Revenue Growth
+6.67%
P/S Ratio
0.72
Revenue / Employee
1.43B
Employees
290
Market Cap
297.83B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 385.19B | 249.51M | 0.06% |
| Dec 31, 2023 | 384.95B | -10.11B | -2.56% |
| Dec 31, 2022 | 395.06B | 56.08B | 16.54% |
| Dec 31, 2021 | 338.98B | 94.67B | 38.75% |
| Dec 31, 2020 | 244.31B | -27.39B | -10.08% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 220.74B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 159.27B |